Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

VNRX

VolitionRX Ltd

Dec 05 • 04:00PM ET

0.5722

Dollar change +0.0042
Percentage change 0.74	%

Healthcare • Diagnostics & Research • USA • AMEX

Peers: TMO BIO CRL ILMN EXAS QGEN DGX GH NEO MYGN

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.36	Insider Own	24.27%	Shs Outstand	92.39M	Perf Week	-17.88%
Market Cap	53.02M	Forward P/E	-	EPS next Y	-0.21	Insider Trans	0.67%	Shs Float	70.17M	Perf Month	-4.63%
Income	-29.87M	PEG	-	EPS next Q	-0.07	Inst Own	18.91%	Short Float	0.78%	Perf Quarter	-18.01%
Sales	1.29M	P/S	41.10	EPS this Y	35.00%	Inst Trans	-	Short Ratio	4.09	Perf Half Y	-17.07%
Book/sh	-0.23	P/B	-	EPS next Y	35.38%	ROA	-194.48%	Short Interest	0.55M	Perf Year	-16.47%
Cash/sh	0.06	P/C	9.80	EPS next 5Y	-	ROE	-5396.85%	52W Range	0.43 - 1.23	Perf YTD	-20.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	2.75%	ROI	-	52W High	-53.48%	Beta	1.19
Dividend TTM	-	Quick Ratio	0.22	Sales past 5Y	188.43%	Gross Margin	-4.34%	52W Low	33.04%	ATR (14)	0.08
Dividend Ex-Date	-	Current Ratio	0.22	EPS Y/Y TTM	30.73%	Oper. Margin	-2331.90%	RSI (14)	37.37	Volatility	15.05% 13.60%
Employees	110	Debt/Eq	-	Sales Y/Y TTM	97.50%	Profit Margin	-2323.23%	Recom	1.50	Target Price	3.17
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	38.19%	Payout	-	Rel Volume	3.63	Prev Close	0.57
Sales Surprise	-27.15%	EPS Surprise	3.45%	Sales Q/Q	187.22%	Earnings	Nov 15 BMO	Avg Volume	133.52K	Price	0.57
SMA20	-17.59%	SMA50	-16.46%	SMA200	-20.25%	Trades		Volume	485,128	Change	0.74%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-01-23	Downgrade	The Benchmark Company	Buy → Hold
Feb-17-22	Resumed	Cantor Fitzgerald	Overweight	$8 → $7
Mar-10-21	Initiated	Cantor Fitzgerald	Overweight	$8
May-16-18	Initiated	Maxim Group	Buy	$6
May-14-18	Reiterated	The Benchmark Company	Buy	$7 → $5
Sep-07-16	Reiterated	Rodman & Renshaw	Buy	$12 → $10
Feb-01-16	Initiated	Rodman & Renshaw	Buy	$12

Nov-16-24 02:02AM	VolitionRX Ltd (VNRX) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
Nov-15-24 05:32AM	VolitionRX: Q3 Earnings Snapshot (Associated Press Finance) -5.56%
Nov-14-24 04:10PM	VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update (PR Newswire) -5.76%
07:19AM	VolitionRX Ltd (VNRX) Q3 2024 Earnings Report Preview: What to Look For (GuruFocus.com)
Nov-08-24 08:00AM	VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update (PR Newswire) +5.44%
04:10PM	Loading…
Nov-06-24 04:10PM	Volition Appoints Timothy I. Still as Chairman (PR Newswire) +9.29%
Oct-31-24 08:00AM	Multiple studies show Nu.Q NETs test could predict sepsis patients at risk of deteriorating (PR Newswire) -9.39%
Oct-09-24 08:00AM	Volition to share new 'NETs in sepsis management' data insights at upcoming webinar (PR Newswire) -9.42%
Oct-03-24 08:00AM	Volition hosts NETs in sepsis management symposium at ESICM Lives 2024 (PR Newswire) +9.32%
Sep-30-24 04:10PM	Volition Appoints Dr. Ethel Rubin as an Independent Director (PR Newswire) +5.82%
Sep-20-24 08:35AM	Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire)
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire)
Sep-11-24 08:00AM	Volition Hosts KOL Roundtable on Sepsis (PR Newswire) +7.21%
Aug-14-24 05:31PM	VolitionRX: Q2 Earnings Snapshot (Associated Press Finance)
04:10PM	VolitionRx Limited Announces Second Quarter 2024 Financial Results and Business Update (PR Newswire)
08:00AM	Loading…
Aug-09-24 08:00AM	VolitionRx Announces Pricing of up to $21.5 Million Registered Direct Offering (PR Newswire) -7.19%
Aug-06-24 08:00AM	VolitionRx Limited Schedules Second Quarter 2024 Earnings Conference Call and Business Update (PR Newswire)
Jul-09-24 08:30AM	Volition appoints PharmaVentures for Capture PCR and oncology portfolio licensing (PR Newswire)
Jun-27-24 08:00AM	VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual Meeting (PR Newswire)
Jun-14-24 09:00AM	Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
May-29-24 08:00AM	VolitionRx Limited to Present at Jefferies Global Healthcare Conference (PR Newswire) +10.74%
May-15-24 03:01AM	VolitionRX Ltd (VNRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances and ... (GuruFocus.com)
May-13-24 05:11PM	VolitionRX: Q1 Earnings Snapshot (Associated Press Finance) +5.85% -14.53%
04:10PM	VolitionRx Limited Announces First Quarter 2024 Financial Results and Business Update (PR Newswire)
May-08-24 08:00AM	VolitionRx Limited Schedules First Quarter 2024 Earnings Conference Call and Business Update (PR Newswire)
Apr-23-24 08:00AM	Nu.Q Vet Cancer Test launched in-clinic in U.S. and Europe through Antech (PR Newswire) +41.67%
Mar-27-24 12:31PM	VolitionRx Limited (AMEX:VNRX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-25-24 04:10PM	VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update (PR Newswire)
Mar-21-24 08:30AM	VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update (PR Newswire) -8.75%
Mar-20-24 08:30AM	Volition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan (PR Newswire) -5.88%
04:30PM	Loading…
Mar-19-24 04:30PM	Volition appoints Dr Andrew Retter as Chief Medical Officer (PR Newswire)
Feb-02-24 08:00AM	Volition to Share Nu.Q® NETs Strategy Update at Upcoming Webinar (PR Newswire)
Jan-18-24 04:54AM	Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances (InvestorPlace)
Jan-04-24 08:00AM	Volition Issues Business Review 2023 (PR Newswire) -18.10%
Dec-05-23 10:25AM	Sidoti Events, LLC's Virtual December Small-Cap Conference (ACCESSWIRE)
08:00AM	VolitionRx Secures Approximately $5.5 Million in Belgium Regional Government Financing from Wallonie Entreprendre (PR Newswire)
Nov-16-23 09:15AM	VolitionRx Limited (AMEX:VNRX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-15-23 05:08AM	VolitionRX: Q3 Earnings Snapshot (Associated Press Finance)
Nov-14-23 04:10PM	VolitionRx Limited Announces Third Quarter 2023 Financial Results and Business Update (PR Newswire) -7.29%
Nov-08-23 08:00AM	VolitionRx Limited Schedules Third Quarter 2023 Earnings Conference Call and Business Update (PR Newswire) +6.00%
Nov-06-23 06:24AM	Volition and VPG Launch Nu.Q® Vet Cancer Test in UK & Ireland (PR Newswire)
Nov-02-23 08:19AM	VNRX: Breakthrough Cancer Detection Method Disclosed at ESMO and in a Webinar - preliminary proof of concept work indicates simple blood test should be able to detect several types of cancer, potentially at Stages I & II (Zacks) +12.03%
Oct-23-23 08:00AM	Volition Presents Breakthrough Liquid Biopsy Blood Test Method for Early-stage Cancer (PR Newswire) +7.00%
Oct-19-23 08:00AM	Measuring Nucleosomes Using Nu.Q® NETs is a Promising Biomarker for Septic Shock (PR Newswire) -24.17%
Oct-18-23 12:00PM	US Ambassador Adler visits Belgian Volition (PR Newswire) +5.69%
Oct-16-23 08:00AM	Volition Presents Three Cancer Detection Abstracts at ESMO 2023 (PR Newswire)
Oct-13-23 08:00AM	Volition Publishes Key Opinion Leader Roundtable Report on NETs in Sepsis (PR Newswire) +6.45%
Oct-02-23 08:00AM	Volition to Reveal New Cancer Detection Method Insights at Upcoming Webinar (PR Newswire) +8.85%
Sep-13-23 08:00AM	Volition Hosts Key Opinion Leader Roundtable on Sepsis Management (PR Newswire)
Aug-25-23 04:30AM	VolitionRx (VNRX): Review of 2Q 2023; Distribution Footprint of Nu.Q Vet Cancer Test is expanding. Prolific Schedule of Clinical Papers & Posters. (Zacks)
Aug-14-23 05:27PM	VolitionRX: Q2 Earnings Snapshot (Associated Press Finance)
04:10PM	VolitionRx Limited Announces Second Quarter 2023 Financial Results and Business Update (PR Newswire)
Aug-09-23 08:00AM	VolitionRx Limited Schedules Second Quarter 2023 Earnings Conference Call and Business Update (PR Newswire)
Jun-23-23 04:10PM	VolitionRx Limited Announces Exercise of Over-Allotment Option by Underwriters (PR Newswire)
06:00AM	VNRX: Highlights of Capital Markets Day (Nu.Q NETs & Nu.Q Vet); Heska being acquired by Mars (increases Nu.Q Vet distribution footprint); 13 MM share offering completed (Zacks Small Cap Research)
Jun-05-23 04:10PM	VolitionRx Limited Announces Closing of $16.5 Million Underwritten Public Offering of Common Stock (PR Newswire)
Jun-01-23 09:15AM	VolitionRx Limited Announces Pricing of $16.5 Million Underwritten Public Offering of Common Stock (PR Newswire)
May-31-23 04:01PM	VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock (PR Newswire) +8.41%
May-11-23 12:45PM	VolitionRX: Q1 Earnings Snapshot (AP Finance)
07:00AM	Volition Study shows Nucleosome Concentrations are a useful tool for Canine Cancer Treatment Monitoring (PR Newswire)
May-10-23 04:10PM	VolitionRx Limited Announces First Quarter 2023 Financial Results and Business Update (PR Newswire)
May-05-23 08:00AM	VolitionRx Limited Schedules First Quarter 2023 Earnings Conference Call and Business Update (PR Newswire)
Apr-26-23 07:30AM	VolitionRx Limited to Host Capital Markets Day at the NYSE on Thursday May 11. (PR Newswire)
Apr-24-23 09:00AM	Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV (ACCESSWIRE) -6.78%
Mar-15-23 04:10PM	VolitionRx Limited Announces Full Fiscal Year 2022 Financial Results and Business Update (PR Newswire) -15.38% +11.69%
Mar-10-23 08:35AM	Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire)
08:00AM	VolitionRx Limited Schedules Full Year 2022 Earnings Conference Call and Business Update (PR Newswire)
Mar-07-23 08:35AM	Life Sciences Virtual Investor Forum Agenda Announced for March 9th (GlobeNewswire)
Mar-06-23 04:30PM	VolitionRx Limited to Webcast Live at VirtualInvestorConferences.com March 9th (GlobeNewswire)
Feb-27-23 04:42AM	VNRX: Nu.Q Vet Cancer Test Being Launched by Supply Agreement Partners Heska and IDEXX; 4.945 million Share Offering Completed to Help Fund Managements Initiatives (Zacks Small Cap Research)
Feb-22-23 04:10PM	VolitionRx Limited Announces Closing of $8.7 Million Underwritten Public Offering of Common Stock (PR Newswire)
Feb-17-23 08:30AM	VolitionRx Limited Announces Pricing of $7.525 Million Underwritten Public Offering of Common Stock (PR Newswire)
Feb-16-23 04:10PM	VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock (PR Newswire)
08:00AM	Volition's Nu.Q® Vet Cancer Test Now Available for Pre-Order at The Point-of-Care Through Heska Corporation (PR Newswire)
Jan-23-23 08:00AM	Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on January 25, 2023 (GlobeNewswire)
Jan-20-23 08:30AM	Volition to Take Part in Nu.Q® Vet Commercial Strategy Webinar (PR Newswire)
Jan-17-23 10:00AM	Sidoti's January Micro-Cap Conference (ACCESSWIRE)
Jan-12-23 08:00AM	Volition Announces Expansion of Availability of the Nu.Q® Vet Cancer Test Through IDEXX's Reference Laboratory Network (PR Newswire)
Jan-08-23 12:00PM	Volition Issues Business Review 2022 (PR Newswire)
Dec-05-22 08:30AM	Stock Pitch World Cup(TM), Educational Panels and 49 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on December 6-8, 2022 (ACCESSWIRE) -6.70%
Nov-14-22 04:10PM	VolitionRx Limited Announces Third Quarter 2022 Financial Results and Business Update (PR Newswire) +6.02%
08:30AM	Volition Announces Clinical Research Study with Oncovet (PR Newswire)
Nov-10-22 08:30AM	Volition to Participate in a Lung Cancer Screening Study in France (PR Newswire)
Nov-03-22 08:30AM	Volition Announces the Launch of the Nu.Q® Vet Cancer Screening Test in the U.S. and Europe Through Heska's Reference Laboratories (PR Newswire)
08:10AM	VNRX: Global Supply Agreement for Nu.Q Vet Cancer Test with a market leader in pet healthcare. U.S. Clinical studies for Nu.Q NETs are planned to pave the way for FDA approval. (Zacks Small Cap Research)
Oct-20-22 08:00AM	Volition Signs Global Supply Agreement for Nu.Q® Vet Cancer Test (PR Newswire) +22.76%
Oct-11-22 08:05AM	Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics (ACCESSWIRE) -5.63%
Oct-04-22 07:30AM	UPDATE - Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on October 4, 2022 (GlobeNewswire) +5.04%
Sep-30-22 09:00AM	Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on October 4, 2022 (GlobeNewswire) -5.56%
Sep-16-22 08:35AM	Life Sciences Virtual Investor Conference: Presentations Now Available for On-Demand Viewing (GlobeNewswire) -5.14%
Sep-12-22 08:35AM	VolitionRx Limited to Webcast Live at VirtualInvestorConferences.com September 15th (GlobeNewswire)
08:35AM	Life Sciences Virtual Investor Conference Agenda Announced for September 15th (GlobeNewswire)
Aug-16-22 03:00PM	Sidoti's August Micro-Cap Virtual Conference (ACCESSWIRE)
08:00AM	Volition Appoints Mickie Henshall as an Independent Director (PR Newswire)
Aug-10-22 04:10PM	VolitionRx Limited Announces Second Quarter 2022 Financial Results and Business Update (PR Newswire)
08:00AM	Volition Announces U.S. Clinical Study for NETs (PR Newswire)
Aug-08-22 08:00AM	Volition Appoints DXOCRO to Spearhead U.S. FDA Strategy (PR Newswire)
Aug-03-22 08:00AM	VolitionRx Awarded $1.5 Million in Non-Dilutive Funding (PR Newswire)
07:00AM	VolitionRx Limited to Present at Investor Summit Group's Q3 Virtual Conference (Newsfile)
Aug-02-22 04:10PM	VolitionRx Limited Announces Closing of $6.9 Million Underwritten Public Offering of Common Stock (PR Newswire)

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Innes Guy Archibald	Director	Aug 20 '24	Buy	0.67	150,000	100,500	406,683	Aug 21 08:26 AM
Eight Corp Ltd	10% Owner	Jan 02 '24	Sale	0.90	20,000	18,000	298,419	Jan 03 10:41 AM
Eight Corp Ltd	10% Owner	Dec 15 '23	Sale	0.75	20,000	15,000	318,419	Dec 20 10:31 AM
Butera Salvatore Thomas	CEO - Volition Veterinary	Dec 18 '23	Buy	0.83	10,000	8,300	99,350	Dec 19 10:59 AM
Butera Salvatore Thomas	CEO - Volition Veterinary	Dec 15 '23	Buy	0.77	10,000	7,700	89,350	Dec 18 09:38 AM
Rootsaert Rodney Gerard	Secretary	Dec 13 '23	Buy	0.60	10,000	6,000	78,652	Dec 14 09:11 AM
Reynolds Cameron John	President and CEO	Dec 08 '23	Buy	0.67	10,000	6,700	1,704,518	Dec 11 08:51 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VNRX

VolitionRX Ltd

Upgrade your FINVIZ experience